Better long-term prognosis thanks to modern treatment options

Over the past two decades, the arsenal of disease-modifying therapies for multiple sclerosis (MS) has expanded considerably. This applies in particular to the relapsing-remitting form (RRMS), but the treatment options for the other subtypes have also improved. The evidence base for what is currently the only immunomodulatory therapy for primary chronic progressive MS (PPMS) has recently been expanded by several new studies.